炎症反应是糖尿病心肌病发生发展的关键因素

2019-05-31 xujing 中国循环杂志

糖尿病心肌病是一种慢性进展性的疾病,一旦出现心功能障碍,将不可避免地发展为心力衰竭。

糖尿病心肌病是一种慢性进展性的疾病,一旦出现心功能障碍,将不可避免地发展为心力衰竭。

同济大学附属东方医院刘中民、庄儒麟等在本刊发表综述,结合相关研究数据指出,炎症反应是糖尿病心肌病发生、发展过程中的关键因素,淋巴细胞、炎症因子和炎症相关的信号通路都参与其中。

因此,控制炎症的始发因素,调控特定的细胞亚群或者相关的炎症通路可能预防或者改善糖尿病心肌病的进程和病理过程。

然而,不同效应性细胞亚群在糖尿病心肌病发生中的作用及其迁移的机制仍不清楚。

拮抗炎症的起始因素如 RAS 和激肽系统等能否有效抑制炎症反应并减轻糖尿病心肌病的病理、生理过程仍有待于进一步的研究。

深入探索炎症反应在糖尿病心肌病发生、发展过程中的作用机制,或能为有效预防和治疗糖尿病心肌病提供新的思考和方案。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2030748, encodeId=28da2030e4830, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Sun Dec 08 02:51:00 CST 2019, time=2019-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320879, encodeId=876613208e93a, content=<a href='/topic/show?id=43de6e0076f' target=_blank style='color:#2F92EE;'>#炎症反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67007, encryptionId=43de6e0076f, topicName=炎症反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sun Jun 02 13:51:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622389, encodeId=474d1622389bb, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sun Jun 02 13:51:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367127, encodeId=123036e12790, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210319/8535b99e11f8425ea0d00535473afd64/2d2121d6fde646e4b4ea8d46ebb52b92.jpg, createdBy=e2423643634, createdName=133d9d3cm85暂无昵称, createdTime=Sat Jun 01 15:44:26 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042481, encodeId=0e341042481c7, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Jun 01 01:51:00 CST 2019, time=2019-06-01, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2030748, encodeId=28da2030e4830, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Sun Dec 08 02:51:00 CST 2019, time=2019-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320879, encodeId=876613208e93a, content=<a href='/topic/show?id=43de6e0076f' target=_blank style='color:#2F92EE;'>#炎症反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67007, encryptionId=43de6e0076f, topicName=炎症反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sun Jun 02 13:51:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622389, encodeId=474d1622389bb, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sun Jun 02 13:51:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367127, encodeId=123036e12790, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210319/8535b99e11f8425ea0d00535473afd64/2d2121d6fde646e4b4ea8d46ebb52b92.jpg, createdBy=e2423643634, createdName=133d9d3cm85暂无昵称, createdTime=Sat Jun 01 15:44:26 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042481, encodeId=0e341042481c7, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Jun 01 01:51:00 CST 2019, time=2019-06-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2030748, encodeId=28da2030e4830, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Sun Dec 08 02:51:00 CST 2019, time=2019-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320879, encodeId=876613208e93a, content=<a href='/topic/show?id=43de6e0076f' target=_blank style='color:#2F92EE;'>#炎症反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67007, encryptionId=43de6e0076f, topicName=炎症反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sun Jun 02 13:51:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622389, encodeId=474d1622389bb, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sun Jun 02 13:51:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367127, encodeId=123036e12790, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210319/8535b99e11f8425ea0d00535473afd64/2d2121d6fde646e4b4ea8d46ebb52b92.jpg, createdBy=e2423643634, createdName=133d9d3cm85暂无昵称, createdTime=Sat Jun 01 15:44:26 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042481, encodeId=0e341042481c7, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Jun 01 01:51:00 CST 2019, time=2019-06-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2030748, encodeId=28da2030e4830, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Sun Dec 08 02:51:00 CST 2019, time=2019-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320879, encodeId=876613208e93a, content=<a href='/topic/show?id=43de6e0076f' target=_blank style='color:#2F92EE;'>#炎症反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67007, encryptionId=43de6e0076f, topicName=炎症反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sun Jun 02 13:51:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622389, encodeId=474d1622389bb, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sun Jun 02 13:51:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367127, encodeId=123036e12790, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210319/8535b99e11f8425ea0d00535473afd64/2d2121d6fde646e4b4ea8d46ebb52b92.jpg, createdBy=e2423643634, createdName=133d9d3cm85暂无昵称, createdTime=Sat Jun 01 15:44:26 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042481, encodeId=0e341042481c7, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Jun 01 01:51:00 CST 2019, time=2019-06-01, status=1, ipAttribution=)]
    2019-06-01 133d9d3cm85暂无昵称

    学习了,谢谢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2030748, encodeId=28da2030e4830, content=<a href='/topic/show?id=71353e8964f' target=_blank style='color:#2F92EE;'>#发生发展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37896, encryptionId=71353e8964f, topicName=发生发展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=346311, createdName=wgsun, createdTime=Sun Dec 08 02:51:00 CST 2019, time=2019-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320879, encodeId=876613208e93a, content=<a href='/topic/show?id=43de6e0076f' target=_blank style='color:#2F92EE;'>#炎症反应#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67007, encryptionId=43de6e0076f, topicName=炎症反应)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b73f484, createdName=lsj628, createdTime=Sun Jun 02 13:51:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622389, encodeId=474d1622389bb, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Sun Jun 02 13:51:00 CST 2019, time=2019-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367127, encodeId=123036e12790, content=学习了,谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210319/8535b99e11f8425ea0d00535473afd64/2d2121d6fde646e4b4ea8d46ebb52b92.jpg, createdBy=e2423643634, createdName=133d9d3cm85暂无昵称, createdTime=Sat Jun 01 15:44:26 CST 2019, time=2019-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1042481, encodeId=0e341042481c7, content=谢谢MedSci提供最新的资讯, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Sat Jun 01 01:51:00 CST 2019, time=2019-06-01, status=1, ipAttribution=)]
    2019-06-01 misszhang

    谢谢MedSci提供最新的资讯

    0

相关资讯

Cell Signal: 在烟曲霉角膜炎中Wnt5a有助于dectin-1和LOX-1诱导的炎症反应产生

青岛大学附属医院眼科的Che C和Li C等人近日在Cell Signal杂志上发表了一篇重要的工作。真菌性角膜炎会导致严重的角膜溃疡,会引起严重的视力损害,甚至失明。Wnt5a作为激活非经典Wnt信号传导途径的配体,可以诱发炎性趋化因子的产生和中性粒细胞的趋化性迁移。在这项研究中,他们旨在研究Wnt5a在真菌角膜炎中的作用。

Nature:阻断CAR-T“杀人风暴”!大牛团队揭示致命性细胞因子风暴缘起,现有高血压药物或可预防

近期《自然》杂志上刊登了一项来自约翰·霍普金斯大学团队的成果,研究者们发现细胞因子释放与肾上腺素等儿茶酚胺类物质有关,限制其合成可以有效控制CRS发生!在多种免疫治疗癌症的小鼠模型中,这种方法都能够降低细胞因子产生、增加存活率,同时并未影响到治疗效果。

Int J Mol Sci:利用人类胚胎干细胞衍生的视网膜色素上皮细胞建立研究死细胞清除和炎症反应的新模型

匈牙利德布勒森4032医学院的Szatmári-TóthM等人近日在Int J Mol Sci杂志上发表了一篇文章,他们建立了人胚胎干细胞衍生的RPE细胞作为研究负责吞噬的细胞是如何去除RPE细胞的新模型。

Sci Trans Med:帕金森治疗新策略,有望2022年临床试验

帕金森(PD)是一种发病率仅次于阿尔兹海默症的神经衰退性疾病,是威胁中老年人健康和生命的“第三杀手”。近日,《Science Translational Medicine》期刊发表一项最新研究揭示了一种小分子,有望阻止PD进展。

Sci Rep:机器人辅助腹腔镜前列腺癌根治术中异丙酚对炎症反应的作用研究

机器人辅助的腹腔镜前列腺癌根治术(RALRP)是一种微创手术;然而,一些外科手术创伤仍旧能够激发系统炎症。更多的是,RALRP期间的腹腔集气能够诱导再灌注损伤(IRI)。异丙酚是一种麻醉剂,且已知其具有抗炎症和抗氧化的特性。最近,有研究人员比较了异丙酚与地氟醚在RALRP中的炎症和IRI中的作用,具体是通过测量不同的生物标记和围手术期肾功能评估来比较的。研究包括了50名接受地氟醚(n=25)或者异

J Endod:Pentraxin 3调节人牙髓细胞的炎症反应

研究显示,Pentraxin 3 (PTX3)是一个全新的炎症相关疾病的炎症标记物。这篇研究的目的是为了评估PTX3在人牙髓细胞(HDPCs)炎症反应中的作用。